Navigation Links
Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference
Date:5/6/2008

HAYWARD, Calif., May 6 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) announced today that Jane Green, Kosan's Vice President, Corporate Communications, will present at the Leerink Swann Solid Tumors Roundtable Conference in New York at the Grand Hyatt Hotel on Friday, May 9, 2008 at 11:10 a.m. EDT. A live webcast of the presentation can be accessed through http://www.wsw.com/webcast/leerink15/kosn/.

Interested parties may also access a live webcast of the presentation by visiting the "Events Calendar" page under the "Investors/Press" tab on Kosan's website at http://www.kosan.com. A recorded replay of the presentations will be available for two weeks.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- a Hsp90 (heat shock protein 90) inhibitor and an epothilone. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with Velcade(R) (bortezomib) in patients with multiple myeloma in a clinical program called TIME. Tanespimycin is also being studied in HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in a Phase 2 clinical trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroesophagel reflux disease, is in a Phase 1 trial. For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.


'/>"/>
SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results
2. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
3. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
4. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
5. Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
6. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
7. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
8. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
9. Kosan Announces February 28, 2008 Conference Call and Webcast
10. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
11. Kosan Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb. 8, 2016  NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), ... Eugene Seymour , MD, MPH, will present information about the company,s ... Hotel in New York City . ... the Windsor Room at 5:30PM EST. Registered attendees can request a ... York City . --> New York ...
(Date:2/8/2016)... , Feb. 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that its new website ... pharmacy resource–user-centric, story-driven, knowledge-based and mobile-friendly. Visit the ... ... ... "The goal was to ...
(Date:2/6/2016)... ... 06, 2016 , ... The Center for Excellence in Education (CEE) will sponsor ... on Wednesday February 10, 2016. This Bite of Science session, hosted by the ... at 1500 Remount Road in Front Royal, VA from 5:00 p.m. to 8:00 p.m. ...
(Date:2/5/2016)... -- ATCC, the premier global biological materials resource and ... life science researchers that are working to address the ... CDC website . --> CDC website ... single-stranded RNA virus of the Flaviviridae family, genus Flavivirus, ... Viruses. Zika virus is transmitted to humans primarily through ...
Breaking Biology Technology:
(Date:2/3/2016)... 4, 2016 --> --> ... M (105.0), up 1,187% compared with fourth quarter of 2014. ... 517.6 M (loss: 30.0). Earnings per share increased to SEK ... 537.4 M (neg: 74.7). , --> ... to SEK 2,900.5 M (233.6), up 1,142% compared with 2014. ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS devices ... primarily focused on medical screening and diagnostic ... parameters. Wearable devices that facilitate and assure ... of movement are being bolstered through new ... biomedical signal acquisition coupled with wireless connectivity ...
(Date:2/2/2016)... , Feb. 2, 2016   Parabon ... from the U.S. Army Research Office and the ... range and sensitivity of the company,s Snapshot ... Accounting Mission and, more generally, defense-related DNA forensics. ... phenotyping capabilities (predicting appearance and ancestry from DNA ...
Breaking Biology News(10 mins):